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Background: Chinese herbal medicine (CHM) has been used in China and some other countries for the treatment
of patients with functional dyspepsia (FD). However, controlled studies supporting the efficacy of such treatments
in patients with FD are lacking. In this trial, we aimed to assess the efficacy and safety of modified LiuJunZi
decoction in patients with FD of spleen-deficiency and qi-stagnation syndrome.
Methods: We performed a randomized, double-blind, placebo-controlled trial with patients from five centers.
Patients with FD of spleen-deficiency and qi-stagnation syndrome (n = 160) were randomly assigned to groups
given CHM modified LiuJunZi decoction or placebo in a 2:1 ratio. Herbal or placebo granules were dissolved in
300 ml of boiled water cooled to 70°C. Patients in both groups were administered 150 ml (50°C) twice daily. The
trial included a 4-week treatment period and a 4-week follow-up period. The primary outcomes were dyspepsia
symptom scores, measured by the total dyspepsia symptom scale and the single dyspepsia symptom scale at
weeks 0, 1, 2, 3, 4 and 8. The secondary outcome was the change of radiopaque barium markers emptied from the
stomach between week 0 and week 4 of treatment.
Results: Compared with patients in the placebo group, patients in the CHM group showed significant
improvements according to the scores of total dyspepsia symptoms and single dyspepsia symptoms obtained from
patients (P < 0.01) and investigators (P < 0.01). They also showed an improvement in the number of radiopaque
barium markers emptied from the stomach (P < 0.05).
Conclusions: CHM modified LiuJunZi decoction appears to offer symptomatic improvement in patients with FD of
spleen-deficiency and qi-stagnation syndrome.
Trial registration: Chinese Clinical Trial Registry (ChiCTR): ChiCTR-TRC-10001074
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Functional dyspepsia (FD) is a common functional gas-
trointestinal disorder characterized by chronic or recur-
rent upper abdominal fullness, epigastric pain, belching,
bloating, early satiety, nausea, vomiting, regurgitation,
burning, loss of appetite, and other symptoms. FD ac-
counts for a significant proportion of patients seen in* Correspondence: zhss2000@163.com
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reproduction in any medium, provided the orgastroenterology offices. The global prevalence of FD is
estimated between 11.5% and 29.2% [1-4]. The direct and
indirect economic burden caused by FD is huge and has
considerable negative impact on productivity [5,6]. The
pathophysiology of FD is poorly understood, although
various mechanisms are thought to play a role in the de-
velopment of symptoms [7-10]. No single available treat-
ment is reliably effective for this condition. Many studies
have suggested the potential effectiveness of Chinese
herbal medicine (CHM) in the treatment of FD [11], but
most of the previous clinical trials have lacked rigor and
used poor techniques for randomization and blinding. ToLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Zhang et al. BMC Complementary and Alternative Medicine 2013, 13:54 Page 2 of 9
http://www.biomedcentral.com/1472-6882/13/54date, no strong scientific evidence supporting the use of
CHM in FD is available.
In Traditional Chinese Medicine (TCM), FD is consid-
ered nearly equivalent to the TCM term “stuffiness and
fullness” [12], which is divided into different syndromes
according to the clinical symptoms and signs. In our
previous research, we studied the distribution of the dif-
ferent syndromes in 565 cases of FD and found that
“spleen-deficiency and qi-stagnation” is the most com-
mon syndrome in FD patients [13]. The Chinese consen-
sus on diagnosis and treatment of functional dyspepsia
also defines spleen-deficiency and qi-stagnation as a
prominent syndrome in FD [14]. LiuJunZi decoction is a
traditional Chinese compound herbal recipe for invigo-
rating the spleen and regulating qi. We added the related
herbal medicines Cortex Mangnoliae officinalis, Com-
mon Vladimiria Root, Rhizoma Corydalis, and Villous
amomrum fruit to the recipe, and found a modified
LiuJunZi decoction with a satisfactory clinical effect.
Previous studies had shown that the active ingredients
in the modified LiuJunZi decoction can improve gastro-
intestinal motility, regulate gastrointestinal function and
have anti-Helicobacter pylori and anti-inflammatory ac-
tion [15-21].
In this trial, we aimed to test the efficacy of the modified
LiuJunzi decoction in patients with FD and spleen-
deficiency and qi-stagnation syndrome using a random-
ized, double-blind, placebo-controlled study design.
Methods
Design
This study was a double-blind, placebo-controlled clin-
ical trial. Patients were randomized into CHM or pla-
cebo groups in a 2:1 ratio. Because it would be unethical
to assign an equal number of ill subjects to the ineffec-
tive placebo treatment, the 2:1 randomization plan was
chosen to protect the rights of the subjects. The trial
protocol was approved by regional ethics review boards,
including the National Review Board for Clinical Drug
Research in the Beijing Hospital of Chinese Medicine
Hospital affiliated to Capital Medical University and the
Affiliated Hospital of Nanjing University of Traditional
Chinese Medicine. There were no major changes in the
study protocol after initiation of the study.
Participants
Patients were screened by investigators at five sites in
China: the Beijing Hospital of Traditional Chinese Medi-
cine affiliated to Capital Medical University, the Affiliated
Hospital of Liaoning University of Traditional Chinese
Medicine, the Second Affiliated Hospital of Guangdong
University of Traditional Chinese Medicine, the Affiliated
Hospital of Nanjing University of Traditional Chinese
Medicine, and the Beijing Xuanwu Hospital of TraditionalChinese Medicine. The study was conducted between
April 2009 and February 2011. Patients were assessed
according to the Rome III criteria and the Guiding prin-
ciple for clinical research on new drugs of traditional
Chinese medicine [12]. The inclusion and exclusion cri-
teria are shown in Table 1. Written informed consent was
obtained from all patients prior to inclusion in the trial.
Patients were free to withdraw from the study at any time.
Randomization and blinding
Randomization was performed with SAS9.10. Eligible pa-
tients were assigned a randomization number according to
a predetermined list at each center. These numbers were
allocated to patients in sequential order and registered in
the patient enrolment list and the allocation was concealed.
Emergency envelopes containing the randomization code
were provided to the investigators and were examined at
the end of the trial to ensure that the blinded conditions
had been maintained.
Interventions
Patients in CHM group were provided granules of Chinese
herbal extracts, which were prepared by Tcmages Pharma-
ceutical Co., Ltd. (Beijing, China). The standard herb for-
mula (Table 2) was a modified LiuJunZi decoction.
Patients in the placebo group were given placebo granules,
which were prepared by the same supplier and were
designed to taste, smell and look similar to the Chinese
herbal formula granules. Granules were dissolved in
300 ml boiled water cooled to 70°C. Patients in both
groups were required to take 150 ml (50°C) twice daily.
For the duration of the trial, the patients were not allowed
to take any concomitant medications associated with the
treatment of FD. Treatment continued for 4 weeks and
was followed by a 4-week follow-up period.
Outcomes
Primary outcome
We assessed FD symptoms using two scales: 1) the total
dyspepsia symptoms scale and 2) the single dyspepsia
symptom scale. Ratings were completed by both the in-
vestigators and patients at baseline and at weeks 1, 2, 3,
4 and 8.
Total dyspepsia symptom scale (TDS) The TDS scale
consisted of the assessment of eight items (postprandial
fullness and bloating, early satiety, epigastric pain, epi-
gastric burning, nausea, vomiting, belching and “other
symptoms”), each with four options (absent = 0, mild = 1,
moderate = 2, or severe = 3).
Single dyspepsia symptom scale (SDS) The SDS scale
measured three aspects of four principal symptoms of FD.
The symptoms were epigastric pain, epigastric burning,
Table 1 Inclusion, exclusion and spleen-deficiency and qi-stagnation syndrome diagnostic criteria
Inclusion criteria 1. Patients who meet the Rome III diagnosis standard of functional dyspepsia.
2. Patients who have Spleen-deficiency and qi-stagnation syndrome.
3. Patients aged 18 to 65 without gender limitation.
4. Signed the informed consent.
Exclusion criteria 1. Patients who combined with GI ulcer, erosive gastritis, atrophic gastritis, severe dysplasia of gastric
mucosa or suspicious malignant lesion.
2. Patients who have overlap syndrome combined with gastroesophageal reflux disease or irritable
bowel syndrome.
3. Patients whose syndrome is difficult to differentiate.
4. Patients who have connective tissue diseases, diabetes or other endocrine disease, climacteric
syndrome, or severe diseases in heart, liver, lung, kidney, blood.
5. Pregnant or lactating women. Disabled people.
6. Patients with history of alcoholic or drug abuse.
7. Patients who have allergic constitution or known to be allergic to the drug used in this trial.
8. Patients who are involved in other trials.
9. Patients with poor compliance or other reasons that the researcher considered not to be
appropriate to participate in this trial.
10. Patients with severe depression and have suicidal tendency.
Spleen-deficiency and qi-stagnation
syndrome diagnostic criteria
The spleen-deficiency and qi-stagnation syndrome is defined as having the main symptoms and
at least two of the accompanying symptoms, as well as pale tongue with whitish tongue coating
and deep and thready pulse. The main symptoms include epigastric stuffiness and fullness, and
asthenia. While the accompanying symptoms include epigastric stuffiness and fullness aggravated
after meal, epigastric pain, decreased appetite, belching and acid regurgitation, fullness and
discomfort in chest and hypochondrium, nausea and vomiting, and constipation or loose stool.
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three aspects were the frequency, intensity and level of
discomfort, and were rated by four options (absent = 0,
mild = 1, moderate = 2, or severe = 3). The total score
obtained using this scale was called the single dyspepsia
symptom (SDS) score.
The secondary outcome
Gastric emptying trial using radiopaque barium
markers Patients ate the standard meal and 20 barium
markers after fasting for 6–8 hours. The standard meal
consisted of a bag of instant noodles (97 g) and pork in-
testines (45 g). Abdominal radiographs were taken at 5 -
hours after eating, and the number of residual markersTable 2 Chinese herb formula
Chinese name Pharmaceutical name Powdered herb, %
Dang Shen Pilose Asiabell Root 16.5
Bai Zhu Largehead Atractylodes Rhizoma 11.0
Fu Ling Indian Buead 11.0
Gan Cao Liquorice Root 5.5
Hou Po Cortex Mangnoliae officinalis 11.0
Mu Xiang Common Vladimiria Root 11.0
Sha Ren Villous Amomrum Fruit 6.5
Yuan Hu Rhizoma Corydalis 16.5
Ban Xia Pinellia Tuber 11.0in the stomach was counted. The number of radiopaque
barium markers emptied from the stomach was used as
a measure of gastric emptying.
Safety monitoring
To assess the safety of the 4-week treatment, routine
tests of blood, urine and stool samples, as well as elec-
trocardiogram (ECG) and blood biochemical tests (ALT,
AST, BUN, Scr), were conducted before randomization
and immediately after the completed treatment. During
the trial, adverse events were observed in detail and doc-
umented using case report forms (CRFs).
Sample size
We performed sample size calculations in two ways. To
guarantee the reliability of the trial, the calculation yield-
ing the larger sample size was used. The sample size was
calculated according to the following formula [22]:
n1 ¼ uα
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ










¼ π1 þ cπ2
1þ c ; uα ¼ 1:64; uβ ¼ 1:28;
c ¼ 2;π1 ¼ 0:5;π2 ¼ 0:75
The patients were assigned to either the CHM group
or the placebo group (in a 2:1 ratio). The effective rates
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50%, respectively [23,24]. The calculation indicated that
a sample size of 138 would be sufficient (n = 92 in the
treatment group, n = 46 in control group). To allow for
a 15% rate of dropouts and missing data, we recruited
106 patients for the treatment group and 54 patients for
the control group.Statistical analysis
We used intention to treat (ITT) analyses, using all avail-
able data at each time point and the baseline observation
carried forward (BOCF) approach for missing data. The
statistical analysis was performed by the Center of Clinical
Epidemiology of the Third Hospital of Peking University.
Parametric Student’s t-tests or non-parametric Wilcoxon
tests were used to quantitatively compare variables,
according to distribution characteristics. Quantitative vari-
ables are reported as mean ± SD. Statistical significance
was considered at P < 0.05.Figure 1 The flow of participants in the study.Results
Study population
Between April 2009 and February 2011, a total of 160
patients were recruited: 106 were randomized into the
CHM group and 54 into the placebo group. Seven pa-
tients withdrew from the trial due to a lack of efficacy.
No adverse events were reported. The physiological tests
obtained after 4 weeks of treatment showed no abnor-
mal values.Participant flow
The flow of participants in the study is summarized
in Figure 1.Baseline data
The general characteristics of the patients are shown in
Table 3. No significant differences were identified be-
tween the two groups in parameters such as gender, age,
course of disease or symptom scores before treatment.
Table 3 Baseline date of two groups
Variables CHM (n = 106) placebo (n = 54) P Values
Characteristic P > 0.05
Age(year) 39.48 ±13.75 41.63 ± 12.31
Sex ratio(male:female) 35:71 15:39
Height(Cm) 164.94 ± 7.41 164.57 ± 7.01
Weight(Kg) 58.25 ± 10.04 58.91 ± 9.85
Course of disease(month) 43.24 ± 51.41 45.30 ± 65.42
TDS and SDS scores (week 0)
Gastroenterologist TDS scores 6.58 ± 2.23 6.61 ± 2.11
Patient TDS scores 6.56 ± 2.18 6.81 ± 2.31
Gastroenterologist SDS scores
Epigastric pain 3.32 ± 2.27 2.85 ± 2.10
Epigastric burning 0.98 ± 1.74 0.96 ± 1.67
Postprandial fullness and bloating 5.04 ± 1.97 5.25 ± 1.96
Early satiety 3.35 ± 2.39 3.69 ± 2.33
Patient SDS scores
Epigastric pain 3.25 ± 2.28 2.96 ± 2.27
Epigastric burning 1.00 ± 1.76 1.02 ± 1.79
Postprandial fullness and bloating 5.02 ± 1.93 5.19 ± 1.94
Early satiety 3.33 ± 2.37 3.76 ± 2.44
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Total dyspepsia symptoms scale
After 4 weeks of treatment, the TDS score assessed by
investigators was significantly better for the CHM group
than for placebo (Z = −4.629, P < 0.01). At week 8, the
score was also significantly better for CHM than for pla-
cebo (Z = −3.676, P < 0.01). The TDS scores provided by
the patients themselves were similar to those given by
the investigators (Table 4, Figures 2 and 3).
The results were clinically meaningful. Ratings of the
clinical global impression of improvement after the treat-
ment showed the following significant results for the treat-
ment group vs. placebo group: very much improved
(50.9% vs. 18.5%), much improved (22.6% vs. 29.6%), small
improvement (18.9% vs. 14.8%), and unchanged or deteri-
oration (7.5% vs. 37.0%) (χ2 = 26.559; P < 0.001).Single dyspepsia symptom scale
SDS scores assessed by investigators: After 4 weeks of treat-
ment, the scores of postprandial fullness and bloating, early
satiety, and burning sensation were significantly better
for the CHM group than for placebo (P < 0.01 or P < 0.05).
The score of epigastric pain was not different between the
two groups (P > 0.05). At week 8, the scores of epigastric
pain, postprandial fullness, and early satiety were signifi-
cantly better for CHM than for placebo (P < 0.01). The
score of burning sensation was not different between the
two groups (P > 0.05) (Table 4).The SDS scores provided by patients were similar to
those given by investigators. At week 4, the gastroenter-
ologists’ scores of postprandial fullness and bloating
were lower than the patients’ scores, whereas the gastro-
enterologists gave higher scores for epigastric pain and
early satiety than the patients did. At week 8, the scores
for early satiety given by the gastroenterologists were
higher than those given by patients.The secondary outcome
Gastric emptying using radiopaque barium markers
After CHM treatment, the number of radiopaque barium
markers emptied from the stomach from week 0 to 4 was
significantly higher in the CHM group (5.16 ± 7.53) com-
pared with the placebo group (1.50 ± 3.21) (P = 0.036).Discussion
Functional dyspepsia is a heterogeneous disorder. It
involves many pathogenic factors and different patho-
physiological disturbances, including delayed gastric emp-
tying, impaired accommodation, and hypersensitivity to
gastric distention. Treatment of the underlying patho-
physiological abnormality seems logical, but the main
pharmacotherapeutic options include acid suppression,
prokinetic drugs, and antidepressants [6,25-27], all of
which have limited effects. Herbal formulations are widely
used to treat FD in China and many other areas in the
Table 4 TDS and SDS scores
Variables CHM (n = 106) placebo (n = 54) P Values
Week 1
Gastroenterologist TDS scores 4.73 ± 2.21 5.65 ± 1.96 0.010
Patient TDS scores 4.75 ± 2.24 5.59 ± 1.97 0.021
Gastroenterologist SDS scores
Epigastric pain 2.47 ± 1.91 2.61 ± 1.99 0.668
Epigastric burning 0.74 ± 1.42 1.09 ± 1.86 0.218
Postprandial fullness and bloating 3.70 ± 1.99 4.68 ± 2.02 0.004
Early satiety 2.42 ± 2.16 3.39 ± 2.12 0.008
Patient SDS scores
Epigastric pain 2.42 ± 1.93 2.61 ± 1.99 0.568
Epigastric burning 0.73 ± 1.42 1.11 ± 1.88 0.189
Postprandial fullness and bloating 3.73 ± 2.03 4.63 ± 2.05 0.009
Early satiety 2.39 ± 2.16 3.33 ± 2.06 0.009
Week 2
Gastroenterologist TDS scores 3.44 ± 1.93 5.04 ± 2.11 0.000
Patient TDS scores 3.42 ± 2.02 4.89 ± 2.17 0.000
Gastroenterologist SDS scores
Epigastric pain 1.74 ± 1.81 2.02 ± 1.80 0.350
Epigastric burning 0.58 ± 1.33 0.85 ± 1.50 0.271
Postprandial fullness and bloating 2.92 ± 1.66 4.24 ± 1.89 0.000
Early satiety 1.82 ± 1.93 2.85 ± 2.03 0.003
Patient SDS scores
Epigastric pain 1.69 ± 1.79 1.96 ± 1.78 0.360
Epigastric burning 0.59 ± 1.35 0.85 ± 1.50 0.291
Postprandial fullness and bloating 2.92 ± 1.66 4.26 ± 1.85 0.000
Early satiety 1.83 ± 1.94 2.85 ± 2.02 0.003
Week 3
Gastroenterologist TDS scores 2.63 ± 1.95 4.31 ± 2.23 0.000
Patient TDS scores 2.57 ± 1.98 4.28 ± 2.22 0.000
Gastroenterologist SDS scores
Epigastric pain 1.11 ± 1.65 1.74 ± 1.70 0.028
Epigastric burning 0.27 ± 0.83 0.70 ± 1.34 0.034
Postprandial fullness and bloating 2.15 ± 1.88 3.87 ± 1.96 0.000
Early satiety 1.25 ± 1.82 2.59 ± 1.99 0.000
Patient SDS scores
Epigastric pain 1.11 ± 1.65 1.70 ± 1.71 0.039
Epigastric burning 0.30 ± 0.87 0.70 ± 1.34 0.049
Postprandial fullness and bloating 2.13 ± 1.89 3.83 ± 1.96 0.000
Early satiety 1.19 ± 1.81 2.57 ± 1.95 0.000
Week 4
Gastroenterologist TDS scores 2.03 ± 1.09 3.78 ± 2.35 0.000
Patient TDS scores 1.92 ± 1.89 3.74 ± 2.35 0.000
Gastroenterologist SDS scores
Epigastric pain 0.92 ± 1.54 1.41 ± 1.65 0.061
Epigastric burning 0.20 ± 0.75 0.56 ± 1.22 0.020
Postprandial fullness and bloating 1.60 ± 1.87 3.35 ± 2.04 0.000
Early satiety 0.83 ± 1.55 2.17 ± 1.98 0.000
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Table 4 TDS and SDS scores (Continued)
Patient SDS scores
Epigastric pain 0.90 ± 1.53 1.41 ± 1.65 0.040
Epigastric burning 0.20 ± 0.75 0.56 ± 1.22 0.020
Postprandial fullness and bloating 1.61 ± 1.87 3.35 ± 2.03 0.000
Early satiety 0.79 ± 1.54 2.15 ± 1.99 0.000
Week 8
Gastroenterologist TDS scores 2.08 ± 1.07 3.57 ± 2.46 0.000
Patient TDS scores 1.92 ± 1.84 3.61 ± 2.46 0.000
Gastroenterologist SDS scores
Epigastric pain 0.87 ± 1.59 1.52 ± 1.60 0.005
Epigastric burning 0.20 ± 0.75 0.48 ± 1.18 0.084
Postprandial fullness and bloating 1.64 ± 1.78 3.28 ± 2.24 0.000
Early satiety 0.70 ± 1.47 1.83 ± 2.08 0.000
Patient SDS scores
Epigastric pain 0.86 ± 1.58 1.52 ± 1.60 0.004
Epigastric burning 0.20 ± 0.75 0.48 ± 1.18 0.084
Postprandial fullness and bloating 1.61 ± 1.80 3.20 ± 2.24 0.000
Early satiety 0.73 ± 1.51 1.94 ± 2.04 0.000
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these formulas is inadequate.
This multi-center, randomized, double-blind, placebo-
controlled study indicates that modified LiuJunZi decoc-
tion is effective in the management of symptoms associated
with FD and gastric emptying. The effects appeared to
last for up to 4 weeks after completion of treatment, and
were particularly beneficial for postprandial fullness and
bloating and early satiety. Patients receiving modified
LiuJunZi decoction treatment demonstrated significantly
better outcomes (both clinically and statistically) on all
the outcome measures compared with patients receiving
placebo. Moreover, no adverse events were reported during
the study.
The evaluation of treatment effects in FD is difficult
and there is currently no gold standard. In our study, we
used two different parameters as the main target vari-
ables. The TDS scale included almost all symptomsFigure 2 TDS score-change (by gastroenterologists).associated with FD, and the SDS scale included informa-
tion on the four principal symptoms of FD, measured in
terms of the frequency, intensity and level of discomfort.
The main target variables were recorded by both investi-
gators and patients. We also assessed gastric emptying
with radiopaque barium markers as a more objective
outcome. Another difficulty in clinical trials with pa-
tients with FD is the remarkable placebo response. It has
been shown that one third of patients with FD will re-
spond to placebo in short-term trials [28], and the pro-
portion may be even higher in long-term studies. In our
study, we made a great effort to make the treatments in
the two groups indistinguishable for the patients. A pla-
cebo of similar appearance, smell and taste to the active
concoction was used. To ensure that the patients were
not able to discriminate between placebo and active treat-
ment, 20 healthy volunteers participated in a randomized
taste and visual assessment of the placebo and active
Figure 3 TDS score-change (by patients).
Zhang et al. BMC Complementary and Alternative Medicine 2013, 13:54 Page 8 of 9
http://www.biomedcentral.com/1472-6882/13/54medication. Eight volunteers correctly identified the active
compound as active, whereas twelve volunteers consid-
ered the placebo preparation to be the active compound.
Thus, it is reasonable to assume that the medication was
given in an appropriately blinded manner. Despite the
well-known high response rate to placebo in FD, we found
significantly greater improvements in dyspepsia symptoms
and gastric emptying in patients receiving the CHM com-
pared with placebo-treated patients.
In TCM, injury by food or drink, emotional injury,
and congenital defects are main pathogenic factors of
FD. All these pathogenic factors cause abnormal func-
tion of the upper abdomen, spleen and stomach. Spleen-
deficiency and qi-stagnation exist throughout the course
of the disease. The herbal formula provided to patients
in this study was a modified LiuJunZi decoction. All the
herbs matched well, and could replenish the deficiencies,
and harmonize and regulate the qi. Because the function
of the spleen and stomach recovered, all the dyspepsia
symptoms were abated and the gastric emptying im-
proved. This is accordance with previous studies [15-21]
which showed physiological effects of LiuJunZi decoc-
tion and some other herbal medicines in the modified
LiuJunZi decoction. In Japan, LiuJunZi decoction is used
for functional dyspepsia and has been found to improve
the symptoms in patients, regulation of gastrointestinal
function and hormone secretion [29,30]. However,
herbal preparations are complex and contain a number
of active ingredients that may work together. The
multiple effects of different active ingredients may be
of benefit for the variety of different symptoms that
occur in functional gastrointestinal disorders. How-
ever, more studies are needed to explore the mecha-
nisms of action and properties of the identified
components. FD is a common, chronic and recurrent
functional gastrointestinal disorder. This study used a
short treatment period and follow-up and a relatively
small number of patients, so there is ample room to
enhance the evaluation of efficacy and safety by fur-
ther studies.Conclusion
We conclude that modified LiuJunZi decoction may offer
symptomatic improvements in patients with FD. In this
randomized, double-blinded, placebo-controlled trial, mod-
ified LiuJunZi decoction was shown to be effective in the
management of FD. Further studies are needed to deter-
mine the precise mechanisms of action.
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